tradingkey.logo

Biomerica Inc

BMRA
View Detailed Chart

2.880USD

-0.050-1.71%
Close 09/19, 16:00ETQuotes delayed by 15 min
7.33MMarket Cap
LossP/E TTM

Biomerica Inc

2.880

-0.050-1.71%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.71%

5 Days

-3.36%

1 Month

-3.03%

6 Months

-46.88%

Year to Date

+19.96%

1 Year

+13.53%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
142 / 207
Overall Ranking
405 / 4720
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
Growing
The company is in a growing phase, with the latest annual income totaling USD 5.31M.
Overvalued
The company’s latest PE is -10.72, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 405.55K shares, decreasing 31.74% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 21.13K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.18.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
Ticker SymbolBMRA
CompanyBiomerica Inc
CEOMr. Zackary S. Irani
Websitehttps://biomerica.com/
KeyAI